Holmusk, a leading data science and health technology company, announced a $21.5 million funding round. The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals.The new funding round allows Holmusk to expand its US operations in New York City, and enables investment in its proprietary technology to harness and analyze real-world data to accelerate drug development and data-driven medicine.
Holmusk’s real-world evidence (RWE) platform for behavioral health and chronic diseases seeks to expand data-driven, evidence-based care for people managing behavioral health conditions. This is done by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that care professionals, health care payers, and consumers can use to make fully informed care and treatment decisions, and better integrate care for people with both behavioral and chronic health needs. These capabilities can also aid pharmaceutical companies with R&D and commercialization of new drugs.
Founded in 2015, Holmusk is headquartered in Singapore with offices in New York City, London and Shanghai. Holmusk provides a real-world evidence platform for mental health and chronic diseases.
This was reported by Holmusk on May 18, 2020.